9 minute read
Sep. 5, 2023

A CNS-Penetrant KRASG12C Inhibitor Intended for CNS-Metastatic Cancers


brain-penetrant KRAS G12C inhibitor initial discovery for KRAS G12C-positive tumors from structure-based drug design J. Med. Chem., July 3, 2023 AstraZeneca, Cambridge, UK


Molecules of the Month - July 2023

MOTY Nominees

Molecule of the Year